BioVie Inc. (NASDAQ:BIVI) Short Interest Down 25.0% in April

BioVie Inc. (NASDAQ:BIVI) saw a large drop in short interest during the month of April. As of April 15th, there was short interest totalling 1,110,000 shares, a drop of 25.0% from the March 31st total of 1,480,000 shares. Based on an average trading volume of 2,540,000 shares, the short-interest ratio is currently 0.4 days.

BioVie Stock Performance

Shares of NASDAQ BIVI traded up $0.01 during trading on Monday, reaching $0.50. 1,130,037 shares of the company traded hands, compared to its average volume of 2,084,630. The firm’s fifty day simple moving average is $0.72 and its 200 day simple moving average is $1.71. BioVie has a 12-month low of $0.45 and a 12-month high of $8.69.

BioVie (NASDAQ:BIVI) last posted its quarterly earnings data on Monday, February 12th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.32) by $0.10. On average, equities analysts forecast that BioVie will post -1 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Jump Financial LLC acquired a new stake in BioVie in the third quarter valued at $34,000. Summit Trail Advisors LLC purchased a new position in shares of BioVie during the third quarter worth about $34,000. Finally, Crescent Grove Advisors LLC purchased a new position in shares of BioVie during the third quarter worth about $38,000. 4.59% of the stock is currently owned by institutional investors and hedge funds.

BioVie Company Profile

BioVie Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease.